aMoon Growth I

www.amoon.fund ; www.amoon.fund/growth

Venture Capital Fund

Fully invested

Tech Verticals Preferences

Biotechnology, Deep Tech, Digital Health, Healthtech, Medical Devices, MedTech, Pharmaceuticals

General Data

Management Company:	aMoon Partners
Vintage Year	2018
Current Active Portfolio Companies:	9
Reg. Number:	abCDe

DESCRIPTION

aMoon Growth I leads investment in mid-to-later-stage companies approaching significant value-inflection points, well-positioned to access high-quality opportunities at the convergence of healthcare and technology. The fund invests in bio, pharma, medical device and digital health companies.

Related Funds

Fund Name	Fund Capital($m)	Status	Remarks
aMoon Velocity	abCDe	Final Closing
aMoon Edge	abCDe	N/A
aMoon Growth II	abCDe	Final Closing

CONTACT INFO

Expand / Collapse All

Main Address: Raanana, Israel

Address	34 Jerusalem Rd., Gamla Bldg., Entrance B, 6th Floor
City	Raanana
Country	Israel
Zip	4350110

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Dr. Yair Schindel	Managing Partner & Co-Founder	SNC (CEO)

	CAPITAL RAISED

Date

Amount

Apr. 17, 2018

abCDe

17/04/18 - $200M invested by Marius and three other leading investors. 16/05/18 - $250M invested by Credit Suisse. 11/2018 - the fund has passed its original $500 million target 03/2019 - the fund closed at $660m 07/2020 - raised additional $90m

Limited Partners	Type	Amount	Remarks
abC Defghij*	Institutional Investor	abCDe
abC Defghij	Investment Bank	abCDe
abC Defghij	N/A	abCDe
abC Defghij	Other	abCDe

Investment Data

Managed Capital	abCDe

Preferences

Type of Financing	Equity
Stage Preferences	Initial Revenues,R&D,Revenue Growth

SECTOR SEGMENTATION (By Number Of Companies)

Biomed

74%

Digital Health

13%

Medical Devices

13%

	PORTFOLIO COMPANIES

Current Portfolio Companies (9)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Adicet Bio

Biomed

Second Round

02/10/2019

N/A

$80m

Biolojic

Biomed

Second Round	12/01/2021	N/A	$3.8m
First Round	02/07/2018	N/A	$20m	Warehouse Investment

KAHR

Biomed

Sixth Round	09/01/2026	N/A	$22m
Fifth Round	16/06/2021	N/A	$46.5m

MDClone

Dig. Health

Third Round	01/03/2022	N/A	$63m
Second Round	22/08/2019	N/A	$26m

MiNA

Biomed

First Round

10/09/2020

$30m

£23m.

MOBILion Systems

Biomed

Second Round

17/08/2020

N/A

$35m

Nerivio

Theranica is a developer of electroceuticals, intended to address prevalent neurological pain diseases. The company's product offers an innovative FDA-authorized, non-invasive, smartphone-operated, prescribed wearable use-and-dispose, providing temporary or long-term pain relief, enabling patients to treat acute migraines in an affordable manner.

Third Round	29/08/2022	N/A	$45m
Second Round	18/03/2019	N/A	$33m

StarFinder

N/A

Investment in Fund

01/08/2020

N/A

Ultima Genomics

Biomed

First Round

01/06/2022

$50m

$600m

Exits (5)

Company Name	Exit Type	Date Announced	Amount	Remarks
abC Defghij	Acquired	19/01/2023	abCDe	Share swap deal
abC Defghij	IPO	07/05/2020	abCDe	Delisted following the acquisition by Advaxis Inc. and is now trading on the OTC under the symbol ADXS.
abC Defghij	Acquired	22/11/2023	abCDe
abC Defghij	Acquired	10/08/2021	abCDe	Formerly Zebra Medical Vision, renamed "Nanox AI" following the acquisition by NanoX.
abC Defghij	IPO	03/12/2020	abCDe

Last Updated:	abCDe
IVC Number:	abCDe